ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
From Single-Cell Clusters to Causality: ITCH Engagement for CKD Uncovered by Integrative Analysis of MR and MAGMA.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic kidney disease (CKD) is a leading and rapidly rising contributor to global mortality, yet actionable molecular targets remain limited. Here, we integrated human kidney single-cell RNA sequencing (scRNA-seq) with genetic association and causal inference frameworks to prioritize putative CKD susceptibility genes. To mitigate cell-level pseudoreplication inherent to small-donor scRNA-seq datasets, we primarily implemented a donor-aware pseudobulk strategy to identify differentially expressed genes (DEGs) between CKD and control kidneys, and subsequently prioritized candidates by convergent evidence from Mendelian randomization (MR) and MAGMA gene-level association analyses using CKD-related GWAS summary statistics. Across these complementary layers, ITCH emerged as a high-confidence candidate, showing consistent support from transcriptomic dysregulation and genetic evidence. We further performed immunohistochemistry-based validation in an experimental kidney injury model, providing additional support for ITCH upregulation in diseased kidneys. Finally, to explore potential pharmacological modulation in a hypothesis-generating manner, we conducted DSigDB-based drug enrichment followed by molecular docking and 50-ns molecular dynamics simulations to evaluate structural compatibility and complex stability, nominating hesperetin as a higher-priority compound for subsequent experimental testing. Collectively, our multi-omics integration supports ITCH as a plausible gene involved in CKD pathobiology and provides a rationale for the hypothesis that targeting ITCH could alter disease progression, which warrants future experimental investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.